Illinois Tool Works Inc. vs TransMedics Group Inc — how do they compare? Illinois Tool Works Inc. trades at $292.78 (market cap $83.49B), while TransMedics Group Inc trades at $87.63 (market cap $3.10B). The key difference: Illinois Tool Works Inc. is far larger — about 26.9× TransMedics Group Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ITW | TMDX | |
|---|---|---|
Market Cap | $83.49B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $299.60 | $150.42 |
52-Week Low | $241.07 | $61.99 |
Enterprise Value | $92.34B | $3.49B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
ITW trades at $294.52, down 0.72% today, with bullish technical signals from moving averages and a consensus price target of $314.25 representing 6.7% upside. The company has beaten earnings estimates for three consecutive quarters, maintains strong profitability with 19.39% net margins, and recently announced a 7% dividend increase alongside a $6 billion share repurchase program. Revenue remains stable around $16 billion annually with consistent cash flow generation.
The outlook remains positive given strong operational execution and shareholder returns, though valuation multiples appear elevated with a P/E of 26.55. Key risks include potential margin pressure from economic cycles and high debt levels at 55.54% of assets. The stock offers quality exposure to industrial recovery with disciplined capital allocation.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Trailing returns across standard periods
Latest headlines on both assets
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →